Exegiline Pharma

Company Overview

Snapshot

Founded in December 2020 by Tal Youdim, Dr. Santiago Ini, Prof. Moussa Youdim, and Prof. Eli Heldman, Exegiline Pharma operates with 1–10 employees. The company has secured one funding round from one investor, Youdim Pharmaceuticals. In April 2022, Prof. Moussa Youdim, a founder, was awarded the 2022 Israel Prize in Life Sciences for his pioneering work in neurodegenerative disease treatments, underscoring the scientific foundation of the company's approach.

Business overview

Exegiline Pharma is a Health Tech & Life Sciences company focused on developing novel treatments for neurodegenerative diseases, specifically dementia and Alzheimer's disease. The company's core product is MT-031, a multifunctional oral drug designed to combine the beneficial properties of rivastigmine and rasagiline. MT-031 acts as a dual acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitor, with selective irreversible inhibition of MAO-A, alongside anti-inflammatory, neuroprotective, and cognitive-enhancing activities. Exegiline Pharma operates within the Pharmaceuticals, Drugs Discovery & Development, and Biologicals sectors, targeting the Life Sciences and Healthcare & Life Sciences markets.

Strategic signal

In April 2022, Prof. Moussa Youdim, a founder of Exegiline Pharma, received the 2022 Israel Prize in Life Sciences for his significant contributions to neurodegenerative disease research. This recognition highlights the deep scientific expertise underpinning Exegiline Pharma's drug development efforts, particularly its MT-031 compound for Alzheimer's and dementia. For investors, this signals strong foundational research and potential for innovation in a critical therapeutic area, validating the company's scientific leadership and approach.

Company Intelligence Q&A

What is Exegiline Pharma's primary focus?

Exegiline Pharma is focused on the multifactorial treatment of Alzheimer's disease and dementia through the development of its novel oral drug, MT-031.

What is the key mechanism of action for Exegiline Pharma's lead drug candidate?

Exegiline Pharma's lead drug, MT-031, functions as a dual acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitor, and also provides selective irreversible inhibition of MAO-A. It also exhibits anti-inflammatory, neuroprotective, and cognitive-enhancing properties.

When was Exegiline Pharma founded and by whom?

Exegiline Pharma was founded in December 2020 by Tal Youdim, Dr. Santiago Ini, Prof. Moussa Youdim, and Prof. Eli Heldman.

What significant recognition did a founder of Exegiline Pharma receive?

In April 2022, Prof. Moussa Youdim, a founder of Exegiline Pharma, was awarded the 2022 Israel Prize in Life Sciences for his pioneering work in neurodegenerative disease treatments.

Which entity incubated Exegiline Pharma and provided initial funding?

Exegiline Pharma was established at Youdim Pharmaceuticals, which also provided initial funding in December 2020.